Most Recent Articles by Jennifer Britton-Colonnese, MSN, FNP-BC, CDE
Often, patients as consumers may not be aware that the products they are using for diabetes care are not protected by HIPAA.
The explosion of technological advances in the medical field poses challenges, including cybersecurity and potentially new malpractice claims.
A 25-year-old woman newly diagnosed with type 1 diabetes presents with insidious onset of recurrent hypoglycemia and is given a CGM device.
Endocrinology Advisor Articles
- Higher Complications, Comorbidities in Youth With Type 2 Versus Type 1 Diabetes
- The Handoff: Your Week in Endocrinology News - 3/24/17
- Hepatitis B Therapy Associated With Abnormal Bone Metabolism
- Bisphosphonate Drug Holiday Increases Fracture Risk in Postmenopausal Women
- Diabetes Risk in Elderly Women Increased by Statin Use
- Do Gluten-Free Diets Elevate Type 2 Diabetes Risk?
- Fitbit Pitfalls: Electronic Tracking Devices May Not Provide Increased Weight Loss Benefits
- Differential Adverse Renal Effects With Dapagliflozin, Empagliflozin in Type 2 Diabetes
- Preoperative Glargine Dosing May Affect Perioperative Glycemic Control
- Q&A: Obtaining Informed Consent in Clinical Research
- Canagliflozin/Phentermine Results in Superior Weight Loss in Obesity Without Diabetes
- ENDO 2017: What To Watch For
- Metabolic Bone Toxicity Possible With Certain Hepatitis Antivirals
- Comparative Accuracy of Statin Eligbility Guidelines From the USPSTF, ACC/AHA for African Americans
- Revisiting the Legality of Curbside Consults in Clinical Practice